Discovery of Neutral and Cerebrospinal Fluid Penetrant Transthyretin (TTR) Stabilizers with Heterocyclic Linkers
- 27 September 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22942-22953
Abstract
Human transthyretin (TTR) is associated with ATTR amyloidosis. Despite having approved agents against TTR, there is still an unmet medical need to develop novel agents, especially those that could have therapeutic effects in cerebrospinal fluid (CSF). Structure-based drug design (SBDD) in the thyroxine binding pocket of TTR identified a neutral hit. Further optimization led to compound 9, a neutral TTR tetramer stabilizer with single-digit nM SPR Kd potency and with improved ADME profile that could enable it to penetrate to CSF.Keywords
Funding Information
- Pfizer
This publication has 42 references indexed in Scilit:
- Two Sides of the Same Coin: Transthyretin (TTR) as a Target or Drug Carrier for Drug (Bio)conjugatesJournal of Medicinal Chemistry, 2026
- PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic propertiesEuropean Journal of Medicinal Chemistry, 2023
- Explaining Blood–Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport MechanismsJournal of Medicinal Chemistry, 2023
- Chlorinated Naringenin Analogues as Potential Inhibitors of Transthyretin AmyloidogenesisJournal of Medicinal Chemistry, 2022
- Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and EvaluationJournal of Medicinal Chemistry, 2022
- Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug DeliveryPharmaceutical Research, 2022
- The role of transthyretin in cell biology: impact on human pathophysiologyCellular and Molecular Life Sciences, 2021
- Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related ComorbiditiesJournal of Medicinal Chemistry, 2021
- Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current DevelopmentsJournal of Medicinal Chemistry, 2020
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)Pharmaceutical Research, 2015